Summary
THE most comonly used medical therapies for the treatment of mennorrhagia have been progestogens alone or combined with an oestrogen, and antifibrinolytic drugs. Most recently, prostaglandin synthetase inhibitors have been shown to reduce menstrual blood loss in some women. This paper reviews the use of danazol in the treatment of women complaining of regular but heavy menstrual blood loss and in whom objective measurements of blood loss were made. Eighteen patients with menorrhagia (more than 80 ml menstrual blood loss) were treated with danazol 400 mg daily for 12 weeks. Danazol significantly reduced the menstrual blood loss loss from 231 ± 39ml (mean ± SEM) to 135±33 ml in the first treatment month, and the mean loss thereafter was only 21 ml and 3 ml for the second and third months respectively. A rapid increase in haemoglobin level, and a reduction in the number of days of bleeding were also observed on danazol treatment. No important effect on the coagulation profile was observed during the period of study. Three months after stopping danazol, menstrual blood loss (103 ± 27 ml) was still significantly less than the pre-treatment loss. Because of side-effects of weight gain and muscle cramps in some patients, a smaller dose of danazol, 200 mg daily, has since been evaluated. This dose effectively reduced menstrual loss to acceptable amounts, with continuing regular menstrual periods in most women, and greatly reduced the incidence of side-effects of the drug.
Menorrhagia, which signifies heavy but regular menstrual blood losses, is the commonest symptom with which patients present at the gynaecological clinic. This abnormality may be due to an aberration of function, or herald gross but generally benign disease. It accounts for 25 per cent of patientsattending our own clinic and in one-half of these there is no detectable pathoogy.
We are now seeing an increasing number of patients who naturally have either long or short cycles which they have previously accepted as normal, but who have become worried by an article on cancer in the popular press or by an invitation to have a cervical smear.
There are wide variations of normal menstruation and each woman has her own patterns, which is as much a part of her make-up as the colour of her hair and subject equally to natural or artificial change. No investigation or treatment is necessary for naturally short or long cycles unless they are associated with infertility, inconvenience or a loss so heavy as to cause anaemia. Nevertheless,any change should be investigated immediately as a new pattern may signify malignancy.
Similar content being viewed by others
References
Anderson, A.B.M., Haynes, P.J., Guillebaud, J. and Turnbull, A.C. 1976. Reduction of menstrual blood loss by prostaglandin-synthetase inhibitors.Lancet 1:774.
Barker, M.G., 1968. Psychiatric illness after hysterectomy.British Medical Journal,2:91–95.
Basu, H.K. 1970. Fibrin degradation products in sera of women with normal menstruation and menorrhagia.British Medical Journal,1:74.
Beral, V. and Kay, C.R. 1977. Mortality among oral-contraceptive users.Lancet,2:727.
Bonnar, J., Guillebaud, J., Kasonde, J. and Sheppard, B.L., 1980. Clinical applications of fibrinolytic inhibition in gynaecology.Journal of Clinical Pathology,14 (Suppl. 33): 55–59.
Callender, ST., Warner, G.T. and Cope, E. 1970. Treatment of menorrhagia with tranexamic acid: A double-blind trial.British Medical Journal,4:214.
Chimbira, T.H., Cope, E., Anderson, A.B.M. and Bolton, F.G. 1977. Preliminary results in the treatment of menorrhagia with danazol.Journal of International Medical Research,5 (Suppl. 3), 98.
Chimbira, T.H., Cope, E., Anderson, A.B.M. and Bolton, F.G. 1979. The effect of danazol on menorrhagia, coagulation mechanisms, haematological indices and body weight.British Journal of Obstetrics and Gynaecology,86:46.
Chimbira, T. H., Anderson, A.B.M., Cope, E. and Turnbull, A.C. 1980. Reduction of menstrual blood lossby danazol in unexplained menorrhagia: Lack of effect of placebo.British Journal of Obstetrics and Gynaecology,87:1152–58.
Davidson, J.F., Lockhead, M., McDonald, G.A. and McNichol, G.P. 1972. Fibrinolytic enhancement by stanozolol. A double-blind trial.British Journal of Haematology,22, 543.
Fearnley, G.R. 1973.Advances in Drug Research, Vol. 7,136. Academic Press, London and New York.
Gath, D., Cooper, P. and Day, A. 1982. Hysterectomy and psychiatric disorders. 1. Levels of psychiatric morbidity before and after hysterectomy.British Journal of Psychiatry,140, 335–350.
Green, J.D. and Harris, G.W. 1947. The neurovascular link between the neurohypophysis and adenohypophysis.Journal of Endocrinology,5:136.
Greenblatt, R.B., Dmowski, W.P., Makesh, V.B. and Sholer, H.F.L. 1971. Clinical studies with an antigonadotropin — danazol.Fertility and Sterility,22:102.
Hallberg, L. and Nilsson, L. 1964. Determination of menstrual blood loss.Scandinavian Journal of Clinical and Laboratory Investigation,15:244.
Hallberg, L., Hogdahl, A.-M., Lennart, N. and Goran, R. 1966. Menstrual blood loss and iron deficiency.Acta Medica Scandinavica,180:639.
Hamberg, M., Svensson, J. and Samuelsson,B. 1975. Throm-boxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides.Proceedings of the National Academy of Sciences,72:2994.
Haynes, P.J., Hodgson, H., Anderson, A.B.M. and Turnbull, A.C. 1977. Measurement of menstrual blood loss in patients complaining of menorrhagia.British Journal of Obstetrics and Gynaecology,84:763–768.
Hayne, P.J., Flint, A.P.F., Hodgson, H., Anderson, A.B.M., Dray, F. and Turnbull, A.C. 1980. Studies in Menorrhagia: (a) Mefenamic Acid, (b) Endometrial Prostaglandin Concentrations.International Journal of Gynaecology and Obstetrics,17, 567–572.
Markee, J.E. in Maegs and Stingis (Eds.) 1947.Progress in Gynaecology, (p. 37). Heinemann and Grune, London.
Mikhail, G. 1967. Sex steroids in blood.Clinical Obstetrics and Gynaecology,10:29.
Moncada, S., Gryglewski, R.J., Bunting, S.and Vane, J.R. 1976. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.Nature,263:663.
Nilsson, L. and Bjorkman, S.E. 1965. Experiences with epsilon-aminocaproic acid (epsilon-ACA) in the treatment of profuse menstruation.Acta Medical Scandinavica,77:445.
Nilsson, L. and Rybø, G. 1965. The treatment of menorrhagia with epsilon aminocaproic acid. A double-blind investigation.Acta Obstetrica et Gynacologica Scandinavica,44:467.
Richards, S.H. 1973. Depression after hysterectomy.Lancet 2:430–436.
Ryan, L.J. 1963. The conversion of pregnenolone-7-3H and progesterone-4-14C to oestradiol by a corpus luteum of pregnancy.Acta Endocrinologica,44:81.
Rybø, G. 1966. Plasminogen activators in the endometrium. II Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood loss.Acta Obstetrica et Gynecologica,45:429.
Salvatore, C.A.L. 1958. Arterioles of the endometrium in the etiopathogenesis of dysfunctional haemorrhage.Journal of the International College of Surgeons.29:599.
Vessey, M.P., McPherson, K. and Johnson, B. 1977. Mortality among women participating in the Oxford Family Planning Association Contraceptive Study.Lancet,2:731.
Willman, E.A., Collins, W.P. and Clayton, S.G. 1976. Studies in the involvement of prostaglandins in uterine symptomatology and pathology.British Journal of Obstetrics and Gynaecology,83, 337.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cope, E. The treatment of unexplained menorrhagia. Ir J Med Sci 152 (Suppl 2), 29–32 (1983). https://doi.org/10.1007/BF02945279
Issue Date:
DOI: https://doi.org/10.1007/BF02945279